TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27527817
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection (2‐4mL/s)
Study: 27527817
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (5‐10mL/s)
Study: 27527817
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection
Study: 27527817
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection
Study: 25105547
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (SEP) plus at home nonsupervised exercise therapy (non‐SET)
Study: 21691756
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication
Study: 2162281
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate of 50 l/min
Study: 2162281
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate of 150 l/min
Study: 27379388
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Study: 17083585
Drug: Poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-lactic acid (PLLA) injections
Study: 11423702
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of 68 g olive and 12 g sunflower oil/day (MO; total 80 g)
Study: 11423702
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g corn oil (CO)/day
Study: 3333523
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg slow release once daily
Study: 2943760
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin phosphate applied twice daily for 8 weeks
Study: 23731195
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied twice daily for 8 weeks
Study: 17595452
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (2800 mg daily for 7 days)
Study: 10099043
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 50 mg intramuscularly weekly and 1,000 mg oral calcium carbonate daily (NDC group)
Study: 10099043
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone 1,000 mg oral calcium carbonate daily (CAL group)
Study: 7656846
Drug: Intracoronary bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bisoprolol (0.01 mg/kg body weight)
Study: 7656846
Drug: Intravenous bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bisoprolol (2.5 mg)
Study: 237849
Drug: Bromazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (5 mg t.d.s. for 3 weeks)
Study: 237849
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg t.d.s. for 3 weeks)
Study: 16982107
Drug: Metformin (Met)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Met)
Study: 25402241
Drug: Low risk
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk with varnish (oral health education every three months + varnish biannually)
Study: 25402241
Drug: High risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk with sealant (oral health education every three months + a single application of sealant)
Study: 25402241
Drug: Low risk
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk with sealant (oral health education every three months + a single application of sealant)
Study: 9155961
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg once weekly for 4-6 weeks
Study: 9155961
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg once daily for 4-6 weeks
Study: 7952982
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean 233 mg/day)
Study: 29198188
Drug: 800 g
Normalized name: LEVETIRACETAM 19800 g in 20000 g NOT APPLICABLE POWDER [X]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 g milk
Study: 29198188
Drug: 800 g
Normalized name: LEVETIRACETAM 19800 g in 20000 g NOT APPLICABLE POWDER [X]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 g yogurt
Study: 23683794
Drug: Illicit use
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit use of prescription stimulants (IUPS)
Study: 11157651
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (INR 2.0 to 3.0)
Study: 24316430
Drug: Glycosylated 1,25(OH)2D3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated 1,25(OH)2D3, single oral dose, up to 40-fold the recommended daily dose (0.5μg/subject/day)
Study: 10453590
Drug: Tang Shen
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tang Shen Ning (TSN) + western medicine
Study: 7881702
Drug: Calcium-heparin (12,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin (12,500 IU once daily)
Study: 7881702
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (300 mg twice daily)
Study: 3108922
Drug: 1.5‐5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5‐5 mg haloperidol orally and/or intravenously
Study: 31926142
Drug: Virtual Reality-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality-Based Therapy (VRBT)
Study: 30656509
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.2 mg/mL for 2 min before surgery
Study: 30656509
Drug: Bevacizumab-methylcellulose mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-methylcellulose mixture (BMM) 1.25 mg in 2% methylcellulose injected subconjunctivally after surgery
Study: 25376972
Drug: Adductor Canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor Canal Block (ACB) with ropivacaine 0.2% 30 mL
Study: 25376972
Drug: Femoral Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral Nerve Block (FNB) with ropivacaine 0.2% 30 mL
Study: 23657413
Drug: Corega Brite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corega Brite combined with Oral Balance (artificial saliva)
Study: 17106661
Drug: Short wave
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short wave therapy for 3 weeks
Study: 17106661
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (routine ambulatory care)
Study: 14633141
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1 g twice daily 24 hours before and after angiography
Study: 30637727
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream treatment on upper back
Study: 30341986
Drug: Four serial
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four serial phlebotomy procedures followed by intravenous infusion of placebo normal saline
Study: 24279907
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline spray)
Study: 22796139
Drug: VAX128A (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX128A (up to 8 μg)
Study: 22796139
Drug: VAX128B (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX128B (up to 16 μg)
Study: 22796139
Drug: VAX128C (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX128C (up to 20 μg)
Study: 20430328
Drug: Low-dose BoNT‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose BoNT‐A (100 units)
Study: 20430328
Drug: High-dose BoNT‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BoNT‐A (200 units)
Study: 18492675
Drug: Sock with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sock with nanocapsules containing a hydrating agent
Study: 15968657
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of carbogen
Study: 15968657
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of oxygen
Study: 10916802
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (AECI)
Study: 1562290
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone triiodothyronine (T3) 30 micrograms/day
Study: 3910057
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg bid)
Study: 3554990
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg bid)
Study: 29979837
Drug: Inhaled anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthesia (IA)
Study: 11676576
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (TG)
Study: 9158048
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg of praziquantel in two divided doses administered 6 hr apart at Farshout
Study: 9158048
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg of praziquantel in a single dose at Om El‐Laban
Study: 7954027
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 50 mg/kg intravenously
Study: 2164655
Drug: IVIG, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG, 500 mg/kg
Study: 2164655
Drug: 5% albumin-normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin-normal saline (placebo), 10 ml/kg
Study: 30795705
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg once daily (OD)
Study: 28088032
Drug: Oral cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabidiol (200mg)
Study: 28088032
Drug: Oral cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabidiol (400mg)
Study: 3121718
Drug: Phenelzine, L-tryptophan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine, L-tryptophan, and lithium ('5HT-cocktail')
Study: 20522984
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of rosuvastatin
Study: 20522984
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of rosuvastatin
Study: 18185500
Drug: 0, 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 2.5, and 5 mg intravenous Delta‐9‐THC
Study: 3655000
Drug: 3-g q4h
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g q4h regimen of azlocillin
Study: 3655000
Drug: 5-g q8h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g q8h regimen of azlocillin
Study: 25690082
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP)
Study: 26203099
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g agave inulin/d
Study: 26203099
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g agave inulin/d
Study: 26203099
Drug: Agave inulin
Normalized name: Agave Inulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agave inulin (5.0 g and 7.5 g)
Study: 6141424
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (1000 mg/m2) in addition to conventional oral therapy of mercaptopurine and low-dose methotrexate
Study: 27743432
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic supplements (2 × 10^9 CFU/g each of Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum)
Study: 24865677
Drug: TDEN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDEN vaccine
Study: 10223782
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg policosanol once a day for the next 12 weeks
Study: 1975150
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg/kg)
Study: 6128860
Drug: Vecuronium (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.025 mg/kg maintenance doses)
Study: 26467311
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D plus calcium supplementation (50,000 IU vitamin D3 every 2 weeks plus 1000 mg day(-1) calcium)
Study: 16046582
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/d) for 28 days
Study: 10423764
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg orally 45 min before MIBI injection
Study: 7595735
Drug: FAM2 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM2 regimen (fluorouracil [5‐FU], doxorubicin, and mitomycin) administered every 43 days for seven cycles.
Study: 6968855
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution with magnesium (MgKCP)
Study: 28186383
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 10 days
Study: 20930165
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin treatment)
Study: 9949940
Drug: buspirone (15‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (15‐20 mg/d)
Study: 9817192
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg once daily)
Study: 381073
Drug: Anti-rabies human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-rabies human diploid cell vaccine (HDCV)
Study: 25569817
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 μg/d) alone
Study: 25569817
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 μg/d) and raloxifene hydrochloride (60 mg/d)
Study: 11386488
Drug: Citalopram (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (7 days treatment)
Study: 11677866
Drug: Bisoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol treatment
Study: 2668252
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg bd
Study: 23731101
Drug: Asthma clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma clinic intervention providing education, self-monitoring promotion, regular treatment review, and written asthma action plan
Study: 22126164
Drug: Detailed information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed information on morphine (experimental group)
Study: 31548595
Drug: Capsule (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (3000 IU/day)
Study: 31548595
Drug: Sublingual spray
Normalized name: Myoden, sublingual spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray (3000 IU/day)
Study: 15583924
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT)
Study: 18677970
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of triflusal (600 mg)
Study: 18677970
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of triflusal (600 mg)
Study: 16208839
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg) as augmentation to ongoing antidepressant therapy
Study: 16208839
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg)
Study: 12072038
Drug: Oral soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral soy isoflavone concentrate containing 80 mg of soy isoflavones
Study: 10590004
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine 0.5% ophthalmic solution (Acular)
Study: 6882984
Drug: Treatment-resistant patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant patients after real ECT
Study: 30568305
Drug: Personalized neoantigen-targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neoantigen-targeting vaccines
Study: 26387494
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b monotherapy
Study: 24465022
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham injection)
Study: 18978495
Drug: High-dose apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose apomorphine (APO)
Study: 18978495
Drug: Low-dose apomorphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose apomorphine (APO)
Study: 2624401
Drug: Endoscopic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic laser therapy
Study: 26527790
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg per day) during chemoradiotherapy and as maintenance monotherapy for 12 months
Study: 15330327
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G‐CSF) 5 microg/kg body weight per day subcutaneously
Study: 8098222
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g carbohydrate from flaxseed or 25 g flaxseed mucilage
Study: 8098222
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g flaxseed oil or flour/kg in muffins
Study: 8098222
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g flaxseed/kg in baked muffins
Study: 2436002
Drug: Cilazapril 30
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 30 mg
Study: 10424316
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg
Study: 314724
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (bypass surgery)
Study: 26645256
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (nonsurgical)
Study: 21395104
Drug: Low-calorie dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie dietary supplement containing a small amount of carbohydrates and fats
Study: 15933556
Drug: Pamphlet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlet and videotape promoting judicious use of antibiotics
Study: 8969668
Drug: Drainage with
Normalized name: BAG,AEROSOL DRAINAGE WITH Y CONNECTOR #HSK974Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage with concurrent fistulotomy
Study: 7511740
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lisinopril
Study: 1315483
Drug: lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril and isradipine (combined)
Study: 27285928
Drug: Arg administration
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arg administration (345 μmol Arg HCl/kg BW, 3 times per day)
Study: 27285928
Drug: Arg administration
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arg administration
Study: 25878028
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (50 μg, 100 μg, or 200 μg) plus vilanterol (25 μg)
Study: 25007003
Drug: Quetiapine-XR (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine-XR (mean dose 276 +/- 50 mg/d, range 50-300 mg/d)
Study: 23103305
Drug: Acute lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute lorazepam (2 mg orally)
Study: 20735783
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid for 12 weeks
Study: 31206210
Drug: mCTAR exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCTAR exercise and traditional dysphagia treatment
Study: 20197019
Drug: Test oral
Normalized name: Femtest Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test oral suspension of nimesulide 50 mg/ml
Study: 20197019
Drug: Nisulid 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisulid 100 mg tablet
Study: 19223674
Drug: Sodium‐citrate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium‐citrate plus Gatorade (NaCIT: 170 mmol Na+L(‐1))